Nuvectis Pharma Inc —— 财务报表 (NASDAQ:NVCT) | MetaTrader

展开完整图表

新闻

Nuvectis initiates phase 1b trial combining NXP900 with osimertinib

H.C. Wainwright重申Nuvectis Pharma股票评级为"买入"

Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright

卡普兰以64,240美元购入Nuvectis Pharma (NVCT)股票

Nuvectis Pharma董事长Bentsur购入价值28,600美元的股份

Nuvectis Pharma董事Sanchez以7.5万美元购入NVCT股票

H.C. Wainwright维持Nuvectis Pharma股票买入评级，目标价10美元

H.C. Wainwright reiterates Buy rating on Nuvectis Pharma stock at $10 target

Nuvectis Pharma adds former Intra-Cellular exec to board of directors

Nuvectis initiates phase 1b program for cancer drug NXP900

Nuvectis (NVCT) Q2 Loss Widens 43%

Nuvectis Pharma stock price target lowered to $10 at H.C. Wainwright